Asset
BBO-8520
BridgeBio Oncology Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06343402 | phase1 | recruiting | 2024-05-22 | 2031-04-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.